Several nanomedicines have been approved by the EMA, demonstrating the potential of nanotechnology in improving healthcare. These include Doxil (a liposomal formulation of doxorubicin for cancer treatment), Abraxane (albumin-bound paclitaxel for breast cancer), and Onivyde (liposomal irinotecan for pancreatic cancer). These products leverage the unique properties of nanomaterials to enhance therapeutic efficacy and reduce side effects.
